All posts from in,

Will BioMarin Top Q2 Earnings Again on Vimizim Sales? - Analyst Blog

BioMarin Pharmaceutical Inc. BMRN will be reporting second quarter 2015 earnings on Aug 3 after the market closes.

BioMarin’s track record has been pretty good, with the company reporting narrower-than-expected loss in each of the trailing four quarters with an average beat of 46%. Last quarter, the company delivered a positive earnings surprise of 52.83%.

Vimizim to Drive Sales

Recently launched Vimizim should continue performing well with the company launching the product in additional markets and identifying more Morquio A patients. At the time of reporting first quarter results, BioMarin had raised its guidance for Vimizim to $200–$220 million from $170–$200 million.

Other key products, including Naglazyme, Aldurazyme and Firdapse should continue to perform well. Naglazyme should continue to grow on the back of increasing demand resulting from patient growth and high rates of compliance.

Headwinds remain in the form of negative currency...